Key Highlights

  • GSK plc (LSE:GSK) gained on 13 November 2026 after Europe's medicines committee recommended a Bexsero booster dose for people aged 10 and older.
  • The shares traded around 1,906p in early trade as healthcare stocks helped lift the FTSE 100 to a three-month high.
  • Third-quarter Revenue rose 5% at constant currency to £8.89bn and core operating profit rose 5% to £3.08bn, ahead of forecasts.
  • Falling Vaccine sales overshadowed the beat, sending shares down as much as 7% on 28 October.
  • The FTSE 100 large-cap Value Stock is watched for pipeline news, vaccine trends and full-year guidance.

Why GSK plc (LSE:GSK) Is in Focus Today

GSK plc (LSE:GSK) had a positive regulatory development to start Friday, 13 November 2026. The European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanding the label of its Bexsero meningitis B vaccine to include a single booster dose for people aged 10 and older who received their initial vaccination at least two years earlier.

The recommendation is supported by a phase IIIb trial involving 312 participants, which met its primary endpoint and showed that immune memory from vaccination in infancy can be boosted up to 19 years later. GSK says a booster could help maintain protection into adolescence, when meningococcal disease incidence reaches a second peak. Bexsero is registered in 61 countries, with around 140 million doses distributed since 2015.

Healthcare Joins the Defensive Rally

The news came during a broader rotation into healthcare. As technology stocks slid after Nvidia's Leadership crisis and a global Microsoft outage, investors moved into sectors with steady earnings. Drug makers helped drive the FTSE 100 higher during the week, and GSK was among the healthcare names attracting buyers. The index closed Friday at 10,902.56, up 2.2% for the week.

Third-Quarter Results Recap

On 28 October, GSK reported third-quarter revenue of £8.89bn, up 5% at constant currency and around 1% above analyst forecasts. Core operating profit rose 5% to £3.08bn, beating the £2.93bn consensus. Demand for newer specialty medicines in respiratory, immunology, oncology and HIV drove growth.

However, vaccine sales declined, and that disappointed the market. The shares fell as much as 7% on the day, erasing gains made in early October and leaving them roughly flat for the year. Analysts warned that vaccine weakness points to tougher trading in coming quarters, with shingles vaccine Shingrix maturing in key markets and US vaccine policy creating uncertainty. A £328m charge and faster research spending also raised the bar for Earnings growth.

New Leadership and Pipeline

GSK is now led by chief executive Luke Miels, who took over from Emma Walmsley. His priorities include accelerating the pipeline, particularly in specialty medicines, and managing the impact of Patent expiries on HIV drug dolutegravir later this decade. Investors want evidence that new launches can replace maturing products.

Why GSK Is a Value Stock

GSK plc (LSE:GSK) is classed as a large-cap value stock. It trades at a discount to many global pharmaceutical peers on earnings, offers a solid Dividend and has been buying back shares. The discount reflects concerns about the pipeline, patent cliffs and litigation history, but it also gives room for re-rating if new drugs succeed.

Policy and Tariff Backdrop

The pharmaceutical sector faces policy risk in the US, including drug pricing reforms and potential tariffs on imported medicines. GSK has said it is prepared to mitigate potential financial impacts. Changes in US vaccine recommendations are another Factor for its vaccines business.

Risks to Monitor

Key risks include further vaccine sales declines, clinical trial setbacks, generic competition, US pricing pressure and currency movements. A stronger pound reduces reported earnings from overseas sales.

What Investors Are Watching Next for GSK plc (LSE:GSK)

The European Commission is expected to make a final decision on the Bexsero label expansion following the committee's recommendation. Investors will also watch late-stage trial readouts, US vaccine policy decisions and full-year results in early February, which will include 2027 guidance. Strong pipeline progress could help GSK plc (LSE:GSK) close its valuation gap as a FTSE 100 large-cap value stock.

Market Backdrop on 13 November 2026

The wider market backdrop matters for GSK plc (LSE:GSK). The FTSE 100 closed on Friday, 13 November 2026, at 10,902.56, up 2.2% on the week and at its highest level in three months, while the FTSE 250 slipped 0.5% on the day. UK third-quarter GDP growth of 0.7%, the fastest pace in more than two years, has improved confidence in the domestic economy, even as the Bank of England's rise to 4% and US Treasury yields above 5.1% raise the bar for Equity valuations. Healthcare has been one of the sectors attracting defensive buying, with drug makers helping to drive the FTSE 100 higher across the week. For a large-cap value stock in the FTSE 100, that mix of resilient growth, higher rates and volatile Commodity and technology markets is likely to keep trading active into the end of the year.